R-5280 / Rise Therap - LARVOL DELTA

HAMS-AB-01B: R-5280 in Newly Diagnosed Patients With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Rise Therapeutics LLC | Recruiting ➔ Completed | N=39 ➔ 9 | Trial primary completion date: May 2025 ➔ Nov 2025

Enrollment change • Trial completion • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus